at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more – Fred Hutch News Service

SEATTLE Nov. 18, 2020 Fred Hutchinson Cancer Research Centers latest findings on cell therapies, repairing immune function, and more will be featured at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually Dec. 5 8.

Dr. Stephanie Lee, ASH president and Fred Hutch physician-scientist will kick off the meeting with a fireside chat with Dr. Anthony Fauci. She will also chair ASHs annual E. Donnall Thomas Lecture, named for the Hutchs Nobel laureate Dr. Thomas, who would have turned 100 this year. This lectureship recognizes pioneering research achievements.

Lee shared other meeting highlights:

Follow Lee on Twitter: @StephanieLeeMD.

See below for selected presentations by Fred Hutch researchers, along with Fred Hutch experts to follow on Twitter. Presentations times are in the Pacific time zone.

Reporters requesting additional information or interviews, contact Molly McElroy: mwmcelro@fredhutch.org,206.941.8146 (cell). For media registration for the conference, see the ASH newsroom.

REPAIRING IMMUNE FUNCTION

Damage-Induced Pyroptotic Cell Death Facilitates Regeneration of the Thymus

As a small but mighty butterfly shaped gland in the chest, the thymus is the training ground for T cells to mature into disease-killing machines in the body. But over time, the thymus wears out from stress, infection and age. Finding ways to help repair it could have broad implications for preventing and treating cancer. Dr. Sinead Kinsella, a researcher in the lab of Dr. Jarrod Dudakov, will present findings on a new way of thymus regeneration in which a cell death process called pyroptosis is critical in releasing large numbers of signaling molecules that can trigger the thymus to repair itself. Abstract No. 735 (oral presentation) Monday, Dec. 7, 2020: 2:45 p.m. On Twitter: Dr. Sinead Kinsella: @shinkinsella Dr. Jarrod Dudakov: @Dudakov_lab

T CELL RECEPTOR THERAPY

The immune system plays a key role in detecting tumor antigens and killing cancer cells. But immune response to tumor antigens varies and is often insufficient to prevent tumor growth and relapse. Fred Hutch physician-scientists have identified specific tumor antigens that can be targeted to trigger a potent immune response. The team is creating immunotherapy using genetically modified T cells, called TCR T-cell immunotherapy, to augment these responses in patients.

Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress Dr. Elizabeth Krakowwill present a Phase I trial in progress. It uses a T-cell receptor therapy developed byDr. Marie Bleakleyto treat adult and pediatric patients who have relapsed after receiving a stem cell (blood and marrow) transplant for leukemia or other related conditions. Abstract No. 492 (oral presentation) Sunday, Dec. 6, 2020: 2:15 p.m.

A Shared SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could lead to more targeted precision immunotherapies. But, because hundreds of mutations exist on a tumor, targeting the right neoantigen is crucial to trigger an immune response. Dr. Melinda Biernacki, working with the Hutchs Dr. Marie Bleakley, will present findings that identify a specific neoantigen, SF3B1, present in Myelodysplastic Syndromes (MDS), secondary acute myeloid leukemia (AML) and advanced chronic lymphocytic leukemia (CLL), as a promising target for treatment with immunotherapy. Abstract No. 3265 (poster presentation) Monday, Dec. 7, 2020, 7:00 a.m. 3:30 p.m.

CD19 CAR T-CELL THERAPY

Hutch scientists continue to take deep dives into understanding how CD19 CAR T-cell therapy works and how to make it work better for more patients.

Age, performance status, and comorbidities in relation to IEC-associated toxicities (including ICANS) followed by live Q&A panel discussion Scientific Workshop Thursday, Dec. 3, 2020, 2:45 p.m. 3:17 p.m. To be presented by Jordan Gauthier, MD On Twitter: Dr. Jordan Gauthier: @drjgauthier

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics Findings by Dr. Jordan Gauthier, a clinician-scholar at Fred Hutch, suggest that high levels of IL-15 could improve CD19 CAR T-cell efficacy and in vivo persistence. Abstract No. 1442 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. ASH Virtual Poster Walk Thursday, Dec. 10, 2020, 7 a.m. On Twitter: Dr. Jordan Gauthier: @drjgauthier

Patient-Reported Outcomes at Time of CAR-T Cell Therapy Abstract No. 3485 (poster presentation) Monday, Dec. 7, 2020, 7:00 a.m. 3:30 p.m. To be presented by Erin Mullane, DNP

CD20 CAR T-CELL THERAPY

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Researchers at Fred Hutch have developed a CAR T-cell therapy targeting CD20, a specific protein marker in blood cancers, for treating patients with B-cell non-Hodgkin lymphoma who have relapsed or previously been non-responsive to treatment. Dr. Mazyar Shadman will share early results from the ongoing trial taking place at the Seattle Cancer Care Alliance, the Hutchs clinical-care partner. Abstract No. 1443 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. On Twitter: Dr. Mazyar Shadman: @mshadman

CAR T for AML

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy Abstract No. 1959 (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Quy Le, PhD

MORE CELL THERAPY

Challenges in Cell Therapy: Relapse and Toxicities Live Q&A Even as a growing number of cancer patients benefit from advances in immunotherapy, relapse and toxic side effects from the treatment remain challenging. Dr. Aude Chapuis will discuss new strategies using genetically modified immune cells to improve the next generation of adoptive T cell therapies in the treatment of solid tumor and blood cancers. Scientific Program, Live Q&A Saturday, December 5, 2020, 9:30 a.m. 10:15 a.m.

PRECISION MEDICINE AND AML

Researchers from the lab ofDr. Soheil Meshinchi, a pediatric oncologist and acute myeloid leukemia specialist, are mapping genetic mutations to how well a patient will respond to various treatments. Their presentations show that ongoing genomic profiling work can help guide targeted treatments for patients with AML, which is the deadliest leukemia among children and young adults.

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts Abstract No. 274, (oral presentation) Saturday, Dec. 5, 2020, 2:30 p.m. To be presented by Rhonda E. Ries, MA

Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access Abstract No. 1973, (poster presentation) Sunday, December 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Katherine Tarlock, MD

Mesothelin Expression Is Associated with Extramedullary Disease and PromotesIn VivoLeukemic Growth in Acute Myeloid Leukemia Abstract No. 1993, (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Katherine Tarlock, MD

Target-Informed Repurposing of Immunotherapies in AML a Transcriptome Based Approach for Identifying Immediately Available Therapeutics Abstract No. 2003, (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Amanda R. Leonti, MS

BLOOD CLOTS AND CANCER, COVID-19

Dr. Gary Lyman, a medical oncologist, hematologist and public health researcher, has helped develop treatment guidelines for managing blood clots in cancer patients and more recently in COVID-19 patients. His colleagues will present on the COVID-19 findings at this years ASH. Dr. Lyman is available to speak with media. On Twitter: Dr. Gary Lyman: @gary_lyman

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis Abstract No. 1632 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m.

Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry Abstract No. 204; Session No. 701 (oral presentation) Monday, Dec. 7, 2020: 2:45 PM

HEALTHCARE ECONOMICS

Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada Abstract No. 2516 (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:00 p.m. To be presented by Andrew J. Cowan, MD On Twitter: Dr. Andrew Cowan: @andrewcowanmd Co-author Dr. Veena Shankaran: @ShankaranVeena

CELL BIOLOGY

Distinct Transcriptional signatures distinguish the emergence of multipotent progenitors and hematopoietic stem cells from endothelial precursors in the murine embryo Abstract No. 908, (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. To be presented by Tessa Dignum, BS

Note: Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future.

###

Media Contact: Molly McElroy M:206.941.8146 mwmcelro@fredhutch.org

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of the HIV Vaccine Trials Network.

Go here to see the original:
at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Fred Hutch News Service

Neurons stripped of their identity are hallmark of Alzheimers disease, study finds – Newswise

Newswise Researchers at the University of California San Diego have identified new mechanisms in neurons that cause Alzheimers disease. In particular, they discovered that changes in the structure of chromatin, the tightly coiled form of DNA, trigger neurons to lose their specialized function and revert to an earlier cell state. This results in the loss of synaptic connections, an effect associated with memory loss and dementia.

The findings are published Nov. 13 in Science Advances.

The study was founded on the question: how do neurons in patients with Alzheimers disease differ from neurons in healthy individuals?

Its a fundamental question that would provide the framework and foundation for understanding Alzheimers disease at the cellular level, and thus pave the path for novel therapeutic approaches, said Shankar Subramaniam, professor of bioengineering at the UC San Diego Jacobs School of Engineering.

Subramaniam worked with an interdisciplinary team of engineers and neuroscientists at UC San Diego to answer this question. They started by taking human induced pluripotent stem cells derived from patients with familial Alzheimers disease, which is a hereditary form of Alzheimers, and transformed them into neurons. They used next generation sequencing techniques to look at what genes are being expressed in these neurons and how gene expression is regulated, and then compared how they differ in neurons of healthy individuals.

They discovered that neurons derived from the patients de-differentiate to a precursor state.

In other words, they cease to be neurons, Subramaniam said. This is the key defect observed across a diversity of patients with distinct mutations. The consequences to the brain are dramatic, with loss of synaptic connections leading to cognitive decline.

The researchers observed other defects: neuronal genes are suppressed, so these cells no longer have any instructions telling them that they are neurons; they are in a precursor-like state, which means they can trigger cell growth and divisionthis is unusual because adult brains do not produce new neurons; and they have inflammation, which signals damage or stress.

The same defects were also observed in post-mortem human brain samples from patients with Alzheimers disease. This was validating for our findings because we werent just seeing these mechanisms in the stem cells, but in actual brain samples as well, Subramaniam said.

The researchers traced all of these mechanisms back to changes in the structure of chromatin. Parts of this structure consist of open regions, where genes are expressed or regulated, and other parts consist of closed regions, where gene expression is repressed. In the diseased neurons, some regions that used to be open are now closed, and vice versa. As a consequence, the neurons are not behaving as they should be, Subramaniam explained.

The team is now working on developing drugs to inhibit these mechanisms.

See the rest here:
Neurons stripped of their identity are hallmark of Alzheimers disease, study finds - Newswise

Genetic influences on viral-induced cytokine responses in the lung – DocWire News

This article was originally published here

Mucosal Immunol. 2020 Nov 12. doi: 10.1038/s41385-020-00355-6. Online ahead of print.

ABSTRACT

Infection with respiratory viruses such as influenza, respiratory syncytial virus and coronavirus provides a difficult immunological challenge for the host, where a balance must be established between controlling viral replication and limiting damage to the delicate lung structure. Although the genetic architecture of host responses to respiratory viral infections is not yet understood, it is clear there is underlying heritability that influences pathogenesis. Immune control of virus replication is essential in respiratory infections, but overt activation can enhance inflammation and disease severity. Cytokines initiate antiviral immune responses but are implicated in viral pathogenesis. Here, we discuss how host genetic variation may influence cytokine responses to respiratory viral infections and, based on our current understanding of the role that cytokines play in viral pathogenesis, how this may influence disease severity. We also discuss how induced pluripotent stem cells may be utilised to probe the mechanistic implications of allelic variation in genes in virus-induced inflammatory responses. Ultimately, this could help to design better immune modulators, stratify high risk patients and tailor anti-inflammatory treatments, potentially expanding the ability to treat respiratory virus outbreaks in the future.

PMID:33184476 | DOI:10.1038/s41385-020-00355-6

See more here:
Genetic influences on viral-induced cytokine responses in the lung - DocWire News

Japanese and U.S. astronauts arrive at ISS in SpaceX ship – The Japan Times

Cape Canaveral, Florida The commercially developed SpaceX Crew Dragon ship carrying a group of astronauts, including Japan's Soichi Noguchi, successfully docked with the International Space Station on Monday following its liftoff from NASA's space center a day earlier.

Three NASA astronauts Michael Hopkins, Victor Glover and Shannon Walker and Noguchi of the Japan Aerospace Exploration Agency, made up the crew that will begin a six-month mission at the orbiting laboratory.

"Oh, what a good voice to hear, space station astronaut Kate Rubins called out when the Dragon's commander, Hopkins, first made radio contact. The linkup occurred 422 kilometers above the U.S. state of Idaho.

The second manned flight to the ISS by the Crew Dragon capsule, developed by the U.S. company Space Exploration Technologies Corp., followed a test flight earlier this year with two NASA astronauts.

Noguchi, 55, became the first non-American astronaut to be ferried by NASA's first-ever certified commercial human spacecraft system.

Japan Aerospace Exploration Agency (JAXA) astronaut Soichi Noguchi waves as the crew of a SpaceX Falcon 9 rocket departs to the launchpad for the first operational NASA commercial crew mission at Kennedy Space Center in Cape Canaveral, Florida, on Sunday. | REUTERS

He is a veteran astronaut with experience from two previous space missions, having been aboard the Space Shuttle Discovery in 2005 and a Russian Soyuz spacecraft for a 161-day stay on the ISS between 2009 and 2010.

During his present stay on the ISS through April, Noguchi is expected to carry out experiments involving iPS cells, or induced pluripotent stem cells, which can be converted into any type of cell in the body, according to JAXA.

The SpaceX system is expected to serve as a successor to NASA's Space Shuttle program that was in service for 30 years through 2011, its development ending the subsequent years of reliance on the Russian Soyuz vehicle as the sole means of accessing the ISS.

Seats in the Soyuz have cost NASA around $80 million or more each in recent years, according to a 2019 report by the U.S. space agency's Office of Inspector General. NASA hopes to reduce crew transportation costs through commercial systems developed in the United States.

The latest development is welcome news for Japan, which also has had to rely on the Soyuz vehicle to send its astronauts to the ISS.

NASA officials have highlighted the importance of sending more astronauts to the ISS, which increases the capacity for scientific research in space.

The arrival of the four astronauts raises the total number of crew members aboard the ISS to seven. Permanent human occupancy of the station began in November 2000.

See the rest here:
Japanese and U.S. astronauts arrive at ISS in SpaceX ship - The Japan Times

AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update – BioSpace

Nov. 16, 2020 21:05 UTC

ALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc.. (AgeX; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, reported financial and operating results for the third quarter ended September 30, 2020.

Q3 Highlights

This quarter, we continued to build upon our licensing and collaboration model through our new agreement with ImStem that provides us an avenue for participating financially in potential treatments for COVID-19 and acute respiratory distress syndrome or ARDS. Since the first of the year, AgeX has entered into six agreements that could lead to the development of new cell therapies by our licensees and collaborators, which utilize our core technologies and cell lines with potential future income streams to AgeX, said Greg Bailey M.D., Chairman of AgeX. In addition, expansion of our agreement related to ESI clinical-grade pluripotent stem cell lines will now allow us independence to build ESI cell lines as a to-go-to source for deriving cell based therapeutics across the industry.

Liquidity and Capital Resources

AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. As of November 16, 2020, AgeX has borrowed $5.5 million and may draw additional funds from time to time subject to Juvenescences discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1.0 million in any single draw. More information about the New Loan Agreement can be found in AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods ended March 31, 2020, June 30, 2020, and September 30, 2020 filed with the Securities and Exchange Commission on March 30, 2020, May 14, 2020, August 14, 2020, and November 16, 2020, respectively.

Going Concern Considerations

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, and considering that loans from Juvenescence under the New Loan Agreement will be subject to Juvenescences discretion, AgeX believes that its cash and cash equivalents, the remaining $2.5 million available under the New Loan Agreement and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Third Quarter 2020 Operating Results

Revenues: Total revenues for the third quarter of 2020 were $434,000 as compared with $411,000 for the third quarter of 2019. AgeX revenues are primarily generated from subscription and advertising revenues from the GeneCards online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $40,000 of allowable expenses under AgeXs research grant from the NIH. Revenues from that grant were $41,000 in the same period in 2019.

Operating expenses: Operating expenses for the three months ended September 30, 2020 were $2.8 million as compared to $3.6 million for the same period in 2019. Operating expenses are comprised of research and development expense and general and administrative expenses. On an as-adjusted basis, operating expenses for the three months ended September 30, 2020 were $2.3 million as compared to $3.0 million for the same period in 2019.

The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.

Research and development expenses were $0.8 million during the three months ended September 30, 2020, a $0.6 million decrease from $1.4 million during the same period in 2019. The decrease was primarily attributable to the layoff of 11 research and development personnel in May 2020 and the elimination of shared services payments to Lineage Cell Therapeutics, Inc. (Lineage) with the termination of our Shared Facilities and Services Agreement on September 30, 2019.

General and administrative expenses decreased by $0.3 million to $1.9 million during the three months ended September 30, 2020 from $2.2 million during the same period in 2019 despite an increase in head count resulting from the employment of AgeXs own finance team commencing in October 1, 2019. These increases were offset by a decrease in noncash stock-based compensation expense, travel and related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeXs PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem is AgeXs delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)

September 30, 2020

December 31, 2019

(Unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

1,107

$

2,352

Accounts and grants receivable, net

241

363

Prepaid expenses and other current assets

581

1,339

Total current assets

1,929

4,054

Excerpt from:
AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - BioSpace

Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -…

This article was originally published here

Stem Cells Transl Med. 2020 Nov 11. doi: 10.1002/sctm.20-0132. Online ahead of print.

ABSTRACT

Critical limb ischemia is a condition in which tissue necrosis occurs due to arterial occlusion, resulting in limb amputation in severe cases. Both endothelial cells (ECs) and vascular smooth muscle cells (SMCs) are needed for the regeneration of peripheral arteries in ischemic tissues. However, it is difficult to isolate and cultivate primary EC and SMC from patients for therapeutic angiogenesis. Induced pluripotent stem cells (iPSCs) are regarded as useful stem cells due to their pluripotent differentiation potential. In this study, we explored the therapeutic efficacy of human iPSC-derived EC and iPSC-derived SMC in peripheral artery disease model. After the induction of mesodermal differentiation of iPSC, CD34+ progenitor cells were isolated by magnetic-activated cell sorting. Cultivation of the CD34+ progenitor cells in endothelial culture medium induced the expression of endothelial markers and phenotypes. Moreover, the CD34+ cells could be differentiated into SMC by cultivation in SMC culture medium. In a murine hindlimb ischemia model, cotransplantation of EC with SMC improved blood perfusion and increased the limb salvage rate in ischemic limbs compared to transplantation of either EC or SMC alone. Moreover, cotransplantation of EC and SMC stimulated angiogenesis and led to the formation of capillaries and arteries/arterioles in vivo. Conditioned medium derived from SMC stimulated the migration, proliferation, and tubulation of EC in vitro, and these effects were recapitulated by exosomes isolated from the SMC-conditioned medium. Together, these results suggest that iPSC-derived SMC enhance the therapeutic efficacy of iPSC-derived EC in peripheral artery disease via an exosome-mediated paracrine mechanism.

PMID:33174379 | DOI:10.1002/sctm.20-0132

The rest is here:
Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -...

Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -…

Induced Pluripotent Stem Cells (iPSCs) Market Overview

The Global Induced Pluripotent Stem Cells (iPSCs) Market is showing positive signs of growth. With the current COVID-19 pandemic scenario, new business opportunities are sprouting in the market. Organizations must explore new markets to expand their business globally and locally. For getting a deeper understanding of the emerging trends, the Global Induced Pluripotent Stem Cells (iPSCs) Market report showcases various factors that drive the economy worldwide. Moreover, the companies will get to know the market landscape for the next decade 2020-2027.

The Global Induced Pluripotent Stem Cells (iPSCs) Market report has been uniquely designed to cater to the needs of the businesses of the 21st century. Going digital is the new normal. Moreover, companies can get to understand their strengths and weaknesses after assessing the market. The next decade is going to be ruled by customer-centric services. To align the business operations, the management team can utilize the actionable recommendations offered at the end of the Global Induced Pluripotent Stem Cells (iPSCs) Market report. Factors that can lift or reduce the business are termed as the external factors that also govern the functioning of the market or industries as a whole.

Before designing the blueprint, every business group can go through the Global Induced Pluripotent Stem Cells (iPSCs) Market report to understand the key business areas. For shaping a new business venture or expanding into a new market, every company must look into the opportunities and threats that are lurking in the current market. To make an efficient business plan, corporations need to understand the market dynamics that will shape the market in the forecast period (2020-2027).

Following key players have been profiled with the help of proven research methodologies:

Induced Pluripotent Stem Cells (iPSCs) Market: Competitive Landscape

To get a head start in a new market, every enterprise needs to understand the competitive landscape and the basic rules that have kept the specific market afloat. The global Induced Pluripotent Stem Cells (iPSCs) Market report unravels the secret ingredients used by competitors to meet the demands of their target audience. For specifically understanding the need to balance the capital invested with profits, organizations must use specific indicators. These indicators will not only help in pointing towards growth but also act as an alert to the upcoming threats in the near future. A proper business plan and approach can guarantee a smooth path ahead for every organization.

If the firms believe in offering a memorable experience to their prospective customers, the Global Induced Pluripotent Stem Cells (iPSCs) Market report is going to be very useful. Facts and figures are churned into this investigative report to share the strengths and weaknesses of the company. With new technologies being introduced every day, many new entrants have started their business in the market. So, to understand their approach towards the market, the Global Induced Pluripotent Stem Cells (iPSCs) Market report has a dedicated section. From the financial aspect to legal, the market report covers all the major things required to study the market and put the business plan in action. Not only this, the competitors added in the report can be altered as per the clients needs and expectations. Furthermore, the companies get a basic outline of moves, in the Global Induced Pluripotent Stem Cells (iPSCs) Market report, that can push the business to emerald heights, both in terms of sales and customer generation for the estimated time frame (2020-2027).

Induced Pluripotent Stem Cells (iPSCs) Market Segmentation:

The Induced Pluripotent Stem Cells (iPSCs) Market has been examined into different global market segments such as type, applications, and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Type:

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Application:

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Induced Pluripotent Stem Cells (iPSCs) Market: Scope of the Report

To properly get a deeper understanding of the Global Induced Pluripotent Stem Cells (iPSCs) Market, this detailed report is the best choice for businesses. To boost the business along with gaining an edge over the competition, every enterprise needs to focus on the pain points of the market (under investigation). Our experienced professionals have collated facts and figures.

This in-depth analysis has revealed many fascinating facts for organizations. For smooth functioning, every business needs to be flexible towards the latest market trends. For this, the framework must be designed to adapt to the trends running at the moment. An end-to-end examination done on the target crowd helped in building the fundamental segment of the investigation, namely the external factors. These have a high tendency to push or pull the industries. Entire industries can either flourish or wipe out due to these uncontrollable factors. Global Induced Pluripotent Stem Cells (iPSCs) market report shows the most affordable options for new as well as established business players to gain market share.

With the highly experienced and motivated team at your service, the team also provides the impact of major factors such as Porters five forces. In the Global Induced Pluripotent Stem Cells (iPSCs) Market, every business runs on the image that is generated digitally in the current decade. Hence, companies need to understand the legal hurdles also. Moreover, with the in-depth study conducted across the various market verticals, it is crystal clear that stakeholders also play a significant role in running the business. Get all the details in the Global Induced Pluripotent Stem Cells (iPSCs) Market report and understand your competitors.

Key questions answered through this analytical market research report include:

What are the latest trends, new patterns and technological advancements in the Induced Pluripotent Stem Cells (iPSCs) Market? Which factors are influencing the Induced Pluripotent Stem Cells (iPSCs) Market over the forecast period? What are the global challenges, threats and risks in the Induced Pluripotent Stem Cells (iPSCs) Market? Which factors are propelling and restraining the Induced Pluripotent Stem Cells (iPSCs) Market? What are the demanding global regions of the Induced Pluripotent Stem Cells (iPSCs) Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

More:
Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -...

Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells – BioSpace

Proteintechs recent acquisition of nanobody manufacturer, ChromoTek, has made them a leading player in the nanobody space. ChromoTeks high-performing camelid single-chain recombinant reagents, also known as nanobodies, fuel breakthrough research discoveries.

HebeCell holds unique expertise and intellectual property in induced pluripotent stem cells (iPSC) and their lineage specific differentiation, especially toward natural killer (NK) cells. Although NK cells are best known for killing virally infected cells, they also play key roles in detecting and controlling early signs of cancer.

Partnering with Proteintech will give both companies a competitive edge, said Dr. Allen Feng, the Founder and Chief Scientific Officer of HebeCell, Our combined expertise and technologies create a unique and special collaboration that will improve the treatment and care of cancer patients.

Dr. Jason Li, CEO of Proteintech added, Ive known Dr. John Lu, Founder and CEO of HebeCell, for many years and Im glad we have an opportunity to work together on this important project. With HebeCells proprietary NK cells and Proteintechs nanobodies, the two companies can transform the future of cancer therapy.

About Proteintech Group Inc.

Proteintech is a leading manufacturer of antibodies, proteins and immunoassays across research areas. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. After the acquisition of manufacturer, ChromoTek, Proteintech now provides innovative reagents based on camelid antibodies called nanobodies. Proteintech sites are ISO13485 and ISO9001-2015 accredited.

About HebeCell Corporation

HebeCell, founded in 2016, focuses on the fields of Immunotherapy by developing human induced pluripotent stem cell (iPSC)-based off-the-shelf CAR-natural killer (CAR-NK) and other immune cell therapeutics targeting hematological malignancies and solid tumors, as well as autoimmune and infectious diseases. HebeCell has expertise and assets in iPSC specific lineage cell differentiation and state-of-the-art cGMP cell manufacturing facility. Its first-in-class proprietary 3D manufacturing platform for human iPSC-CAR-NK cells is feeder-free and designed specifically for single-use-bioreactor at industrial scale, which allows rapid deploy off-the-shelf CAR-NK cell products for all patients. HebeCells platform technology will accelerate the application of iPSC cells as a viable source of immune cells in the next generation of immunotherapy and will alter the CAR-NK cell therapy field by delivering cost effective allogenic therapeutics worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005786/en/

See the rest here:
Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells - BioSpace

Global Induced Pluripotent Stem Cells Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2026 -…

There are millions of them around the globe waiting for clutching on to some of the latest vital information circulating across the globe. The up-to-the-minute Induced Pluripotent Stem Cells market report based on the growth and the development of theInduced Pluripotent Stem Cells marketis systematically listed down. The Induced Pluripotent Stem Cells market report comprises statistically verified facts such the unique essence including topological investigations, worldwide market share, government stringent norms, applications, current trends, futuristic plans, market bifurcations, and so on mentioned in a crystal clear pattern.

The statistical plus scientific Induced Pluripotent Stem Cells market report has all the important market aspects penciled down in a layman language format so that the data based on the markets productivity or future strategy can be easily extrapolated from the reports. The Induced Pluripotent Stem Cells market report has the dominant market players Fate Therapeutics, Waisman Biomanufacturing, Bone Therapeutics SA, System Biosciences, Ocata Therapeutics Inc., BrainStorm Cell Therapeutics Inc., CellTherapies P/L, Cellular Dynamics, Lonza, Cellectics, Regeneus Ltd., Stemgent, Iperian, Organogenesis Inc explained in detail.

Sample of global Induced Pluripotent Stem Cells Market Report at::https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003#RequestSample

The essential futuristic segments such as {Adult Sources, Fetal Sources, Others}; {Hematopoietic stem cell transplantation, Tissue repair damage, Autoimmune diseases, As gene therapy vectors.} have also been detailed out in the Induced Pluripotent Stem Cells market report for the clients convenience and more of vital data embracing capability. The forecast trends along with the current market status can better understand the Induced Pluripotent Stem Cells market development on a global basis. The intricate industrial strategies and the supply-demand chain are also discussed in the contextual report.

Key points of the global Induced Pluripotent Stem Cells market

Theoretical analysis of the global Induced Pluripotent Stem Cells market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The Induced Pluripotent Stem Cells market report has the imperative data mentioned in a systematic way only after comprehensive inspection and vigilant referencing. The diagrammatic representations such as a pie chart of the Induced Pluripotent Stem Cells market are also drawn out so as to attract the punters and make it easy for them to comprehend the entire Induced Pluripotent Stem Cells market from in and out. The most eye-catching format of the Induced Pluripotent Stem Cells market report is its market bifurcation based on the product type, application, geography, end-users, and more as per the particular market. The geographical segments Europe, North America, Latin America, Asia Pacific, and Middle East & Africa are further exhaustively mentioned.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003

Questions answered in the report include

1. What is the expected market size by the end of the forecast period? 2. What are the major factors initiating the global Induced Pluripotent Stem Cells market growth? 3. What are the latest developments and trending market strategies that are influencing the growth of the Induced Pluripotent Stem Cells market? 4. What are the key outcomes of the Induced Pluripotent Stem Cells market developments? 5. Who are the key players in the market? 6. What are the opportunities and challenges faced by the key players?

The Induced Pluripotent Stem Cells market report endows the global market dominance, market segmentation, growth factors, and others reported such that the clients can have a total tour of the market without any much off efforts needed.

Key Reasons for Purchasing Global Induced Pluripotent Stem Cells Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

Ask Any Kind of Query Before Purchasing the Report Here:https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003#InquiryForBuying

Read more from the original source:
Global Induced Pluripotent Stem Cells Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2026 -...

Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,…

A New business Strategy report released by DBMR with title Global Stem Cell Manufacturing Market (COVID-19 Version) Study Forecast till 2027. This Market report brings data for the estimated year 2020 and forecasted till 2027 in terms of both, value (US$ MN) and volume (MT).The report also consists of forecast factors, macroeconomic factors, and a market outlook of the market. The study is conducted by applying both top-down and bottom-up approaches and further iterative methods used to validate and size market estimation and trends of the Global Stem Cell Manufacturing Market. This report provides information regarding Stem Cell Manufacturing market size, trends, growth, cost structure, capacity, revenue and forecast 2027.The report explains the moves of top market players and brands that range from developments, product launches, acquisitions, mergers, joint ventures, trending innovation and business policies. Additionally to compliment insights EXIM data, consumption, supply and demand Figures, raw price analysis, market revenue and gross margins.

Stem cell manufacturing is forecasted to grow at CAGR of 6.42% to an anticipated value of USD 18.59 billion by 2027 with factors like rising awareness towards diseases like cancer, degenerative disorders and hematopoietic disorders is driving the growth of the market in the forecast period of 2020-2027.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-manufacturing-market&AB

Stem cell manufacturing has shown an exceptional penetration in North America due to increasing research in stem cell. Increasing research and development activities in biotechnology and pharmaceutical sector is creating opportunity for the stem cell manufacturing market.

The Global Stem Cell Manufacturing Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Manufacturing Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Global Stem Cell Manufacturing Market Segematation By Product (Stem Cell Line, Instruments, Culture Media, Consumables), Application (Research Applications, Clinical Applications, Cell and Tissue Banking), End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others)

List of TOP KEY PLAYERS in Stem Cell Manufacturing Market Report are

Thermo Fisher Scientific Merck KGaA BD JCR Pharmaceuticals Co., Ltd Organogenesis Inc Osiris Vericel Corporation AbbVie Inc AM-Pharma B.V ANTEROGEN.CO.,LTD Astellas Pharma Inc Bristol-Myers Squibb Company FUJIFILM Cellular Dynamics, Inc RHEACELL GmbH & Co. KG Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Ltd ViaCyte,Inc VistaGen Therapeutics Inc GlaxoSmithKline plc ..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-manufacturing-market&AB

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell Manufacturing industry. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell Manufacturing manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The Global Stem Cell Manufacturing Market Trends, development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product, the stem cell manufacturing market is segmented into stem cell lines, instruments, culture media and consumables. Stem cell lines are further segmented into induced pluripotent stem cells, embryonic stem cells, multipotent adult progenitor stem cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells. Instrument is further segmented into bioreactors and incubators, cell sorters and other instruments.

On the basis of application, the stem cell manufacturing market is segmented into research applications, clinical applications and cell and tissue banking. Research applications are further segmented into drug discovery and development and life science research. Clinical applications are further segmented into allogenic stem cell and autologous stem cell therapy.

On the basis of end users, the stem cell manufacturing market is segmented into hospitals and surgical centers, pharmaceutical and biotechnology companies, research institutes and academic institutes, community healthcare, cell banks and tissue banks and others.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Key Insights in the report:

Historical and current market size and projection up to 2025

Market trends impacting the growth of the global taste modulators market

Analyze and forecast the taste modulators market on the basis of, application and type.

Trends of key regional and country-level markets for processes, derivative, and application Company profiling of key players which includes business operations, product and services, geographic presence, recent developments and key financial analysis

For More Information or Query or Customization Before Buying, Visit @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market&AB

Opportunities in the market

To describe and forecast the market, in terms of value, for various segments, by region North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW)

The key findings and recommendations highlight crucial progressive industry trends in the Stem Cell manufacturing Market, thereby allowing players to develop effective long term strategies

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across Europe.

To get a comprehensive overview of the Stem Cell manufacturing market.

With tables and figures helping analyses worldwide Global Stem Cell Manufacturing Market Forecast this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. There are 15 Chapters to display the Stem Cell Manufacturing market.

Chapter 1, About Executive Summary to describe Definition, Specifications and Classification of Stem Cell Manufacturing market, By Product Type, by application, by end users and regions.

Chapter 2, objective of the study.

Chapter 3, to display Research methodology and techniques.

Chapter 4 and 5, to show the Stem Cell Manufacturing Market Analysis, segmentation analysis, characteristics;

Chapter 6 and 7, to show Five forces (bargaining Power of buyers/suppliers), Threats to new entrants and market condition;

Chapter 8 and 9, to show analysis by regional segmentation[North America, Europe, Asia-Pacific etc ], comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain Analysis

Chapter 10, to identify major decision framework accumulated through Industry experts and strategic decision makers;

Chapter 11 and 12, Stem Cell Manufacturing Market Trend Analysis, Drivers, Challenges by consumer behavior, Marketing Channels

Chapter 13 and 14, about vendor landscape (classification and Market Ranking)

Chapter 15, deals with Stem Cell Manufacturing Market sales channel, distributors, Research Findings and Conclusion, appendix and data source.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Originally posted here:
Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,...